Dominique Angèle Vuitton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dominique Angèle Vuitton has a total of 419 co-authors. Here are the top co-authors by number of shared publications:
Solange Bresson-Hadni
Affiliations French National Reference Center for Echinococcosis, Besançon University Hospital, University Bourgogne Franche-Comté, Besançon, France, Hepato-Gastroenterology and Tropical Medicine Units, University Hospital, Geneva, Switzerland
11 shared publications- Hao Wen
State Key Laboratory of Pathogenesis, Prevention, Treatment of High Incidence Diseases in Central Asia, Xinjiang Medical University, China
10 shared publications - Patrick Giraudoux
Chrono-environment, Université Marie et Louis Pasteur/Centre National de la Recherche Scientifique , Besançon
9 shared publications Oleg Blagosklonov
A WHO-Collaborating Centre for Prevention and Treatment of Human Echinococcosis & French National Centre for Alveolar Echinococcosis (Director: Laurence Millon) , University of Franche-Comté and University Hospital , Besançon , France
8 shared publicationsGeorges Mantion
Laboratoire de Toxicologie Cellulaire, EA 4267, Faculté de Médecine et Pharmacie, University of Franche-Comté, Besançon, France
7 shared publications- Junhua Wang
Institute of Parasitology, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland
7 shared publications
Latest Publications
- Open Access
- 29 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10) , ofaf310
Optimizing Health Across Humans, Animals, Plants, and Ecosystems: How Long Before Benefits Turn Harmful—and Harm Becomes Healing?
The One Health framework endorsed by the quadripartite (World Health Organization, World Organisation for Animal Health, Food and Agriculture Organization, and United Nations Environment Program) is defined, in part, as an “integrated, unifying approach that aims to sustainably balance and optimize the health of people, animals, and ecosystems,” and it explicitly refers to the health of plants as part of the whole interrelated system to consider. Although the ultimate issue is the planet's habitability for humans, the definition introduces a shift in perspective—human health is no longer the sole priority but must be balanced and optimized alongside the health of animals, plants, and ecosystems. This raises some practical and ethical questions. Drawing on case studies and the framework of the IPBES (Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services) on the values of nature, this study explores the implications of a global approach to health, with the ethical and practical questions that it raises.
- 29 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10) , ofaf310
Open AccessOptimizing Health Across Humans, Animals, Plants, and Ecosystems: How Long Before Benefits Turn Harmful—and Harm Becomes Healing?
The One Health framework endorsed by the quadripartite (World Health Organization, World Organisation for Animal Health, Food and Agriculture Organization, and United Nations Environment Program) is defined, in part, as an “integrated, unifying approach that aims to sustainably balance and optimize the health of people, animals, and ecosystems,” and it explicitly refers to the health of plants as part of the whole interrelated system to consider. Although the ultimate issue is the planet's habitability for humans, the definition introduces a shift in perspective—human health is no longer the sole priority but must be balanced and optimized alongside the health of animals, plants, and ecosystems. This raises some practical and ethical questions. Drawing on case studies and the framework of the IPBES (Intergovernmental Science-Policy Platform on Biodiversity and Ecosystem Services) on the values of nature, this study explores the implications of a global approach to health, with the ethical and practical questions that it raises.
- 10 October 2023
- Published by Springer Nature
- p. 1153-1204
Cystic and Alveolar Echinococcosis: Fraternal Twins Both in Search of Optimal Treatment
- 10 October 2023
- Published by Springer Nature
- p. 1153-1204
Cystic and Alveolar Echinococcosis: Fraternal Twins Both in Search of Optimal Treatment
- Open Access
- 31 March 2023
- Published by EDP Sciences in Parasite
- Vol. 30, 9
Alveolar echinococcosis in solid organ transplant recipients: a case series from two national cohorts
Alveolar echinococcosis (AE) is a severe parasitic infection caused by the ingestion of Echinococcus multilocularis eggs. While higher incidence and faster evolution have been reported in immunosuppressed patients, no studies have been performed specifically on AE in transplant patients. We searched for all de novo AE cases diagnosed between January 2008 and August 2018 in solid organ transplant (SOT) recipients included in the Swiss Transplant Cohort Study and the FrancEchino Registry. Eight cases were identified (kidney = 5, lung = 2, heart = 1, liver = 0), half of which were asymptomatic at diagnosis. AE diagnosis was difficult due to the low sensitivity (60%) of the standard screening serology (Em2+) and the frequently atypical radiological presentations. Conversely, Echinococcus Western blot retained good diagnostic performances and was positive in all eight cases. Five patients underwent surgery, but complete resection could only be achieved in one case. Moreover, two patients died of peri-operative complications. Albendazole was initiated in seven patients and was well tolerated. Overall, AE regressed in one, stabilized in three, and progressed in one case, and had an overall mortality of 37.5% (3/8 patients). Our data suggest that AE has a higher mortality and a faster clinical course in SOT recipients; they also suggest that the parasitic disease might be due to the reactivation of latent microscopic liver lesions through immune suppression. Western blot serology should be preferred in this population. Finally, surgery should be considered with caution, because of its low success rate and high mortality, and conservative treatment with albendazole is well tolerated.
- 31 March 2023
- Published by EDP Sciences in Parasite
- Vol. 30, 9
Open AccessAlveolar echinococcosis in solid organ transplant recipients: a case series from two national cohorts
Alveolar echinococcosis (AE) is a severe parasitic infection caused by the ingestion of Echinococcus multilocularis eggs. While higher incidence and faster evolution have been reported in immunosuppressed patients, no studies have been performed specifically on AE in transplant patients. We searched for all de novo AE cases diagnosed between January 2008 and August 2018 in solid organ transplant (SOT) recipients included in the Swiss Transplant Cohort Study and the FrancEchino Registry. Eight cases were identified (kidney = 5, lung = 2, heart = 1, liver = 0), half of which were asymptomatic at diagnosis. AE diagnosis was difficult due to the low sensitivity (60%) of the standard screening serology (Em2+) and the frequently atypical radiological presentations. Conversely, Echinococcus Western blot retained good diagnostic performances and was positive in all eight cases. Five patients underwent surgery, but complete resection could only be achieved in one case. Moreover, two patients died of peri-operative complications. Albendazole was initiated in seven patients and was well tolerated. Overall, AE regressed in one, stabilized in three, and progressed in one case, and had an overall mortality of 37.5% (3/8 patients). Our data suggest that AE has a higher mortality and a faster clinical course in SOT recipients; they also suggest that the parasitic disease might be due to the reactivation of latent microscopic liver lesions through immune suppression. Western blot serology should be preferred in this population. Finally, surgery should be considered with caution, because of its low success rate and high mortality, and conservative treatment with albendazole is well tolerated.
- 29 July 2022
- Published by Springer Nature
- p. 1-53
Cystic and Alveolar Echinococcosis: Fraternal Twins Both in Search of Optimal Treatment
- 29 July 2022
- Published by Springer Nature
- p. 1-53
Cystic and Alveolar Echinococcosis: Fraternal Twins Both in Search of Optimal Treatment
- 1 January 2022
- Published by ISTE Group
- p. 109-160
Environnement de la ferme, lait cru et immunité : une étude « sur le terrain » de l’apprentissage de la tolérance
L’étude de cohorte PASTURE qui combine depuis 18 ans dans 5 pays européens des études environnementales, microbiologiques, génétiques, et immunologiques chez des enfants vivant ou non dans des fermes d’élevage laitier montre que la biodiversité des milieux de vie traditionnels ruraux est un rempart à l’augmentation sans précédent de la prévalence des maladies allergiques dans la deuxième moitié du XXème siècle.
- 1 January 2022
- Published by ISTE Group
- p. 109-160
Environnement de la ferme, lait cru et immunité : une étude « sur le terrain » de l’apprentissage de la tolérance
L’étude de cohorte PASTURE qui combine depuis 18 ans dans 5 pays européens des études environnementales, microbiologiques, génétiques, et immunologiques chez des enfants vivant ou non dans des fermes d’élevage laitier montre que la biodiversité des milieux de vie traditionnels ruraux est un rempart à l’augmentation sans précédent de la prévalence des maladies allergiques dans la deuxième moitié du XXème siècle.
- 1 January 2022
- Published by ISTE Group
- p. 161-203
Écologie de la transmission de l’échinocoque multiloculaire
L’échinocoque multiloculaire est un parasite provoquant une maladie mortelle pour les humains, l’échinococcose alvéolaire. La combinaison des recherches menées sur les plateaux du Jura, puis en Chine de l’ouest et au Kirgizhistan, permet d’établir, par une approche écoépidémiologique, un tableau des facteurs écologiques et socio-économiques qui favorisent l’émergence de « paysages à risque » et l’enclenchement de processus qui mènent le parasite jusqu’aux personnes.
- 1 January 2022
- Published by ISTE Group
- p. 161-203
Écologie de la transmission de l’échinocoque multiloculaire
L’échinocoque multiloculaire est un parasite provoquant une maladie mortelle pour les humains, l’échinococcose alvéolaire. La combinaison des recherches menées sur les plateaux du Jura, puis en Chine de l’ouest et au Kirgizhistan, permet d’établir, par une approche écoépidémiologique, un tableau des facteurs écologiques et socio-économiques qui favorisent l’émergence de « paysages à risque » et l’enclenchement de processus qui mènent le parasite jusqu’aux personnes.
- 1 October 2021
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 205 (8) , 1028-1059
Terminologie à utiliser pour l’étude et la prise en charge des échinococcoses : adaptation du consensus international à la langue française
- 1 October 2021
- Published by Elsevier in Bulletin de l'Académie Nationale de Médecine
- Vol. 205 (8) , 1028-1059
Terminologie à utiliser pour l’étude et la prise en charge des échinococcoses : adaptation du consensus international à la langue française
- Open Access
- 17 September 2020
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 14 (9) , e0008566
A case for adoption of continuous albendazole treatment regimen for human echinococcal infections
Cystic (CE) and alveolar (AE) echinococcosis are chronic, neglected parasitic diseases burdened by high morbidity and, for AE, by high mortality, if left untreated. CE and AE have a widespread distribution, including Europe. Albendazole (ABZ), a broad-spectrum benzimidazole drug widely used to treat parasitic infections, is the drug of choice for the management of CE and AE, and is parasitostatic on echinococcal metacestodes. In Europe, ABZ is licensed for interrupted “cyclic” treatment, for a maximum of 3 cycles. However, better efficacy with no increased side effects has been shown when the drug is administered continuously and for longer periods. Current international recommendations, on the basis of clinical, pharmacological, and biological studies, recommend continuous administration of ABZ for months to years for the treatment of CE and AE, and this schedule has been widely in use for the past 20 years. However, in Europe this internationally recommended schedule, with the exception of France, is technically “off-label”, and, as such, requires an informed consent by the patient and, in some countries, even precludes the reimbursement of the drug cost. Adding to the very high cost of the drug, frequent “out-of-stock” situation, and packaging format impractical for long therapies, these conditions put patients with CE and AE regularly at risk of treatment discontinuation and disease progression. European regulations envisage variations to marketing authorization, but postauthorization studies should be carried out by the holder of the license of the drug, in the form of randomized controlled trials. While such studies do not seem feasible and would probably not be ethically justified for CE and AE, European regulations envisage other possibilities in particular situations, which apply to CE and AE, but there is limited interest to invest in this perspective. We urge a coordination between stakeholders to find effective and feasible ways to take action to revise the benzimidazole dosage regimens for CE and AE and to ensure a fair, regular, and easy access to the appropriate treatment to those suffering from these serious diseases.
- 17 September 2020
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 14 (9) , e0008566
Open AccessA case for adoption of continuous albendazole treatment regimen for human echinococcal infections
Cystic (CE) and alveolar (AE) echinococcosis are chronic, neglected parasitic diseases burdened by high morbidity and, for AE, by high mortality, if left untreated. CE and AE have a widespread distribution, including Europe. Albendazole (ABZ), a broad-spectrum benzimidazole drug widely used to treat parasitic infections, is the drug of choice for the management of CE and AE, and is parasitostatic on echinococcal metacestodes. In Europe, ABZ is licensed for interrupted “cyclic” treatment, for a maximum of 3 cycles. However, better efficacy with no increased side effects has been shown when the drug is administered continuously and for longer periods. Current international recommendations, on the basis of clinical, pharmacological, and biological studies, recommend continuous administration of ABZ for months to years for the treatment of CE and AE, and this schedule has been widely in use for the past 20 years. However, in Europe this internationally recommended schedule, with the exception of France, is technically “off-label”, and, as such, requires an informed consent by the patient and, in some countries, even precludes the reimbursement of the drug cost. Adding to the very high cost of the drug, frequent “out-of-stock” situation, and packaging format impractical for long therapies, these conditions put patients with CE and AE regularly at risk of treatment discontinuation and disease progression. European regulations envisage variations to marketing authorization, but postauthorization studies should be carried out by the holder of the license of the drug, in the form of randomized controlled trials. While such studies do not seem feasible and would probably not be ethically justified for CE and AE, European regulations envisage other possibilities in particular situations, which apply to CE and AE, but there is limited interest to invest in this perspective. We urge a coordination between stakeholders to find effective and feasible ways to take action to revise the benzimidazole dosage regimens for CE and AE and to ensure a fair, regular, and easy access to the appropriate treatment to those suffering from these serious diseases.
- 1 August 2020
- Published by Elsevier in Clinical Immunology
- Vol. 217, 108493
A plea for the pathogenic role of immune complexes in severe Covid-19
- 1 August 2020
- Published by Elsevier in Clinical Immunology
- Vol. 217, 108493
A plea for the pathogenic role of immune complexes in severe Covid-19
- Top Cited PapersOpen Access
- 3 June 2020
- Published by EDP Sciences in Parasite
- Vol. 27, 41
International consensus on terminology to be used in the field of echinococcoses
Echinococcoses require the involvement of specialists from nearly all disciplines; standardization of the terminology used in the field is thus crucial. To harmonize echinococcosis terminology on sound scientific and linguistic grounds, the World Association of Echinococcosis launched a Formal Consensus process. Under the coordination of a Steering and Writing Group (SWG), a Consultation and Rating Group (CRG) had the main missions of (1) providing input on the list of terms drafted by the SWG, taking into account the available literature and the participants’ experience; and (2) providing independent rating on all debated terms submitted to vote. The mission of the Reading and Review Group (RRG) was to give an opinion about the recommendation paper in terms of readability, acceptability and applicability. The main achievements of this process were: (1) an update of the current nomenclature of Echinococcus spp.; (2) an agreement on three names of diseases due to Echinococcus spp.: Cystic Echinococcosis (CE), Alveolar Echinococcosis (AE) and Neotropical Echinococcosis (NE), and the exclusion of all other names; (3) an agreement on the restricted use of the adjective “hydatid” to refer to the cyst and fluid due to E. granulosus sensu lato; and (4) an agreement on a standardized description of the surgical operations for CE, according to the “Approach, cyst Opening, Resection, and Completeness” (AORC) framework. In addition, 95 “approved” and 60 “rejected” terms were listed. The recommendations provided in this paper will be applicable to scientific publications in English and communication with professionals. They will be used for translation into other languages spoken in endemic countries.
- 3 June 2020
- Published by EDP Sciences in Parasite
- Vol. 27, 41
Top Cited PapersOpen AccessInternational consensus on terminology to be used in the field of echinococcoses
Echinococcoses require the involvement of specialists from nearly all disciplines; standardization of the terminology used in the field is thus crucial. To harmonize echinococcosis terminology on sound scientific and linguistic grounds, the World Association of Echinococcosis launched a Formal Consensus process. Under the coordination of a Steering and Writing Group (SWG), a Consultation and Rating Group (CRG) had the main missions of (1) providing input on the list of terms drafted by the SWG, taking into account the available literature and the participants’ experience; and (2) providing independent rating on all debated terms submitted to vote. The mission of the Reading and Review Group (RRG) was to give an opinion about the recommendation paper in terms of readability, acceptability and applicability. The main achievements of this process were: (1) an update of the current nomenclature of Echinococcus spp.; (2) an agreement on three names of diseases due to Echinococcus spp.: Cystic Echinococcosis (CE), Alveolar Echinococcosis (AE) and Neotropical Echinococcosis (NE), and the exclusion of all other names; (3) an agreement on the restricted use of the adjective “hydatid” to refer to the cyst and fluid due to E. granulosus sensu lato; and (4) an agreement on a standardized description of the surgical operations for CE, according to the “Approach, cyst Opening, Resection, and Completeness” (AORC) framework. In addition, 95 “approved” and 60 “rejected” terms were listed. The recommendations provided in this paper will be applicable to scientific publications in English and communication with professionals. They will be used for translation into other languages spoken in endemic countries.